Provided by Tiger Trade Technology Pte. Ltd.

SciSparc Ltd.

3.91
-0.0900-2.25%
Post-market: 3.910.00000.00%18:54 EDT
Volume:5.68K
Turnover:22.18K
Market Cap:2.21M
PE:-0.18
High:4.17
Open:3.95
Low:3.67
Close:4.00
52wk High:94.50
52wk Low:3.60
Shares:565.50K
Float Shares:453.20K
Volume Ratio:0.48
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-21.5208
EPS(LYR):-203.8943
ROE:-1281.49%
ROA:-42.05%
PB:--
PE(LYR):-0.02

Loading ...

Scisparc Director Alon Dayan Files Initial Beneficial Ownership Statement

Reuters
·
Mar 24

SciSparc Ltd. CEO and CFO Oz Adler Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Scisparc Ltd. Director Moshe Revach Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

SciSparc Ltd. Director Amitay Weiss Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Scisparc Ltd. files Form 3 initial beneficial ownership statement for Director Lior Vider

Reuters
·
Mar 19

BRIEF-Scisparc Neurothera Labs- Clearmind Medicine Collaboration Leads To Patent Application For Depression Therapy

Reuters
·
Mar 16

NeuroThera Labs files Hong Kong patent application for MEAI-PEA depression therapy

Reuters
·
Mar 16

Scisparc: Neurothera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

THOMSON REUTERS
·
Mar 16

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

THOMSON REUTERS
·
Mar 13

BUZZ-U.S. STOCKS ON THE MOVE -Natera, Pacira BioSciences, Kezar Life Sciences

Reuters
·
Mar 12

BUZZ-SciSparc jumps as unit files patent for obesity, fatty liver treatment

Reuters
·
Mar 12

SciSparc-Controlled NeuroThera Labs Publishes PCT Patent for MEAI-PEA Weight Loss and MASLD Therapy

Reuters
·
Mar 12

Scisparc: Neurothera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

THOMSON REUTERS
·
Mar 12

SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

TIPRANKS
·
Mar 10

Scisparc Ltd - Neurothera to Buy 56,375 Cliniquantum Shares Representing 54.01% Stake

THOMSON REUTERS
·
Mar 10

Scisparc Ltd - Selling Shareholders May Receive Earn-Out Payments up to $2.5 Mln

THOMSON REUTERS
·
Mar 10

Scisparc: Subsidiary Neurothera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in Cliniquantum, Innovator in Quantum-Based Clinical Trails

THOMSON REUTERS
·
Mar 10

Press Release: SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Dow Jones
·
Mar 10

Top Premarket Decliners

MT Newswires Live
·
Mar 10

Scisparc Ltd trading halted, news pending

TIPRANKS
·
Mar 04